162 related articles for article (PubMed ID: 27408122)
1. Dengue Vaccine: The Current Status.
Mustafa MS; Agrawal VK
Med J Armed Forces India; 2008 Apr; 64(2):161-4. PubMed ID: 27408122
[TBL] [Abstract][Full Text] [Related]
2. Review of dengue virus and the development of a vaccine.
Murrell S; Wu SC; Butler M
Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
[TBL] [Abstract][Full Text] [Related]
3. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
Monath TP; Seligman SJ; Robertson JS; Guy B; Hayes EB; Condit RC; Excler JL; Mac LM; Carbery B; Chen RT;
Vaccine; 2015 Jan; 33(1):62-72. PubMed ID: 25446819
[TBL] [Abstract][Full Text] [Related]
4. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
[TBL] [Abstract][Full Text] [Related]
5. Challenges for the formulation of a universal vaccine against dengue.
Chokephaibulkit K; Perng GC
Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
[TBL] [Abstract][Full Text] [Related]
6. Dengue vaccine.
Simasathien S; Watanaveeradej V
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S363-77. PubMed ID: 16858980
[TBL] [Abstract][Full Text] [Related]
7. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
8. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype.
Metz SW; Thomas A; Brackbill A; Xianwen Y; Stone M; Horvath K; Miley MJ; Luft C; DeSimone JM; Tian S; de Silva AM
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006793. PubMed ID: 30248097
[TBL] [Abstract][Full Text] [Related]
11. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
13. Flaviviruses and flavivirus vaccines.
Heinz FX; Stiasny K
Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
[TBL] [Abstract][Full Text] [Related]
14. Current status of flavivirus vaccines.
Barrett AD
Ann N Y Acad Sci; 2001 Dec; 951():262-71. PubMed ID: 11797783
[TBL] [Abstract][Full Text] [Related]
15. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
16. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
[TBL] [Abstract][Full Text] [Related]
18. Latest developments and future directions in dengue vaccines.
Thisyakorn U; Thisyakorn C
Ther Adv Vaccines; 2014 Jan; 2(1):3-9. PubMed ID: 24757522
[TBL] [Abstract][Full Text] [Related]
19. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
